Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies

Herbert Hurwitz, Eric Van Cutsem, Johanna Bendell, Manuel Hidalgo, Chung Pin Li, Marcelo Garrido Salvo, Teresa Macarulla, Vaibhav Sahai, Ashwin Sama, Edward W Greeno, Kenneth H. Yu, Chris Verslype, Fitzroy Dawkins, Chris Walker, Jason Clark, Eileen M. O’Reilly

Research output: Contribution to journal › Article › peer-review

78 Scopus citations

Fingerprint

Dive into the research topics of 'Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies'. Together they form a unique fingerprint.

Medicine & Life Sciences